Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 52, Issue 2, 2017, Pages 183-190

  Whangbo, J ^a,b,c   Ritz, J ^a   Bhatt, A ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; NYSTATIN; POLYMYXIN B; VANCOMYCIN; ANTIINFECTIVE AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL RESEARCH; DISEASE ASSOCIATION; GRAFT VERSUS HOST REACTION; GUT DECONTAMINATION; HISTORY; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INTESTINAL IMMUNE HOMEOSTASIS; INTESTINE FLORA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; ALLOGRAFT; DRUG EFFECTS; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MICROBIOLOGY; MICROFLORA;

ALLOGRAFTS; ANTI-BACTERIAL AGENTS; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MICROBIOTA;

EID: 84982141341     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2016.206     Document Type: Review

References (60)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
2. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH et al. Prospective evaluation of 2 acute graft-versus-host (GvHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005; 106: 1495-1500.
3. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443-458.
4. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55: 905-914.
5. Jenq R, Taur Y, Devlin S, Ponce D, Goldberg J, Ahr KF et al. Intestinal blautia is associated with reduced geath from graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21: 1373-1383.
6. Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res 1971; 45: 577-588.
7. van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401-404.
8. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
9. Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 1994; 152: 1004-1013.
10. Buckner CD, Clift RA, Sanders JE, Meyers JD, Counts GW, Farewell VT et al. Protective environment for marrow transplant recipients: a prospective study. Ann Int Med 1978; 89: 893-901.
11. Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J et al. Graft-versushost disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308: 302-307.
12. Vossen JM, Heidt PJ, van den Berg H, Gerritsen EJ, Hermans J, Dooren LJ. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1990; 9: 14-23.
13. Vossen JM, Guiot HF, Lankester AC, Vossen AC, Bredius RG, Wolterbeek R et al. Complete suppression of the gut microbiome prevents acute graft-versus-host disease following allogeneic bone marrow transplantation. PLoS ONE 2014; 9: e105706.
14. Beelen DW, Haralambie E, Brandt H, Linzenmeier G, Muller KD, Quabeck K et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992; 80: 2668-2676.
15. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267-3275.
16. Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 640-645.
17. Kersun LS, Propert KJ, Lautenbach E, Bunin N, Demichele A. Early bacteremia in pediatric hematopoietic stem cell transplant patients on oral antibiotic prophylaxis. Pediatr Blood Cancer 2005; 45: 162-169.
18. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238.
19. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-2364.
20. Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 2000; 118: 1094-1105.
21. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69: 2277-2285.
22. Cong Y, Brandwein SL, McCabe RP, Lazenby A, Birkenmeier EH, Sundberg JP et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp med 1998; 187: 855-864.
23. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-498.
24. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009; 31: 677-689.
25. Strauch UG, Obermeier F, Grunwald N, Gurster S, Dunger N, Schultz M et al. Influence of intestinal bacteria on induction of regulatory T cells: lessons from a transfer model of colitis. Gut 2005; 54: 1546-1552.
26. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993; 5: 1461-1471.
27. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 2010; 107: 12204-12209.
28. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122: 107-118.
29. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008; 453: 620-625.
30. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011; 331: 337-341.
31. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013; 500: 232-236.
32. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-573.
33. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-455.
34. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-450.
35. Ohnmacht C, Park JH, Cording S, Wing JB, Atarashi K, Obata Y et al. MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity through RORgammat (+) T cells. Science 2015; 349: 989-993.
36. Sefik E, Geva-Zatorsky N, Oh S, Konnikova L, Zemmour D, McGuire AM et al. MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science 2015; 349: 993-997.
37. Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert EA et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014; 513: 564-568.
38. Cebula A, Seweryn M, Rempala GA, Pabla SS, McIndoe RA, Denning TL et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature 2013; 497: 258-262.
39. Morton AM, Sefik E, Upadhyay R, Weissleder R, Benoist C, Mathis D. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. Proc Natl Acad Sci USA 2014; 111: 6696-6701.
40. Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. J Bacteriol 1991; 173: 697-703.
41. Vetrovsky T, Baldrian P. The variability of the 16 S rRNA gene in bacterial genomes and its consequences for bacterial community analyses. PLoS ONE 2013; 8: e57923.
42. Tringe SG, von Mering C, Kobayashi A, Salamov AA, Chen K, Chang HW et al. Comparative metagenomics of microbial communities. Science 2005; 308: 554-557.
43. Tyson GW, Chapman J, Hugenholtz P, Allen EE, Ram RJ, Richardson PM et al. Community structure and metabolism through reconstruction of microbial genomes from the environment. Nature 2004; 428: 37-43.
44. Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124: 1174-1182.
45. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-970.
46. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971-976.
47. Zitvogel L, Galluzzi L, Viaud S, Vetizou M, Daillere R, Merad M et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med 2015; 7: 271ps1.
48. Balmer ML, Schurch CM, Saito Y, Geuking MB, Li H, Cuenca M et al. Microbiota-derived compounds drive steady-state granulopoiesis via MyD88/TICAM signaling. J Immunol 2014; 193: 5273-5283.
49. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013; 13: 790-801.
50. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 2012; 149: 1578-1593.
51. Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209: 903-911.
52. Khosravi A, Yanez A, Price JG, Chow A, Merad M, Goodridge HS et al. Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe 2014; 15: 374-381.
53. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60.
54. Shono Y, Docampo MD, Peled JU, Perobelli SM, Jenq RR. Intestinal microbiotarelated effects on graft-versus-host disease. Int J Hematol 2015; 101: 428-437.
55. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014; 20: 159-166.
56. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5: 193ra91.
57. Joice R, Yasuda K, Shafquat A, Morgan XC, Huttenhower C. Determining microbial products and identifying molecular targets in the human microbiome. Cell Metab 2014; 20: 731-741.
58. Bikel S, Valdez-Lara A, Cornejo-Granados F, Rico K, Canizales-Quinteros S, Soberon X et al. Combining metagenomics, metatranscriptomics and viromics to explore novel microbial interactions: towards a systems-level understanding of human microbiome. Comput Struct Biotechnol J 2015; 13: 390-401.
59. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13: 260-270.
60. Hegazy AN, Powrie F. MICROBIOME. Microbiota RORgulates intestinal suppressor T cells. Science 2015; 349: 929-930.